GLP1R and obesity disorder: GLP1 receptor agonists (GLP1RA) such as semaglutide, liraglutide, and the combined GIP/GLP1RA tirzepatide have revolutionized pharmacotherapy for obesity; initially developed for diabetes treatment, they showed better glycaemic control as well as lower body weight in treated patients and have been approved for obesity management.